GB2447796C - Iodonitrobenzamide formulations for cancer and viral diseases. - Google Patents

Iodonitrobenzamide formulations for cancer and viral diseases. Download PDF

Info

Publication number
GB2447796C
GB2447796C GB0807263A GB0807263A GB2447796C GB 2447796 C GB2447796 C GB 2447796C GB 0807263 A GB0807263 A GB 0807263A GB 0807263 A GB0807263 A GB 0807263A GB 2447796 C GB2447796 C GB 2447796C
Authority
GB
United Kingdom
Prior art keywords
iodonitrobenzamide
formulations
cancer
viral diseases
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
GB0807263A
Other languages
English (en)
Other versions
GB2447796B (en
GB2447796A (en
GB0807263D0 (en
Inventor
Valeria Ossovskaya
Barry Sherman
Lingyun Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BiPar Sciences Inc
Original Assignee
BiPar Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39350967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB2447796(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BiPar Sciences Inc filed Critical BiPar Sciences Inc
Publication of GB0807263D0 publication Critical patent/GB0807263D0/en
Publication of GB2447796A publication Critical patent/GB2447796A/en
Application granted granted Critical
Publication of GB2447796B publication Critical patent/GB2447796B/en
Publication of GB2447796C publication Critical patent/GB2447796C/en
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GB0807263A 2007-01-16 2008-01-16 Iodonitrobenzamide formulations for cancer and viral diseases. Withdrawn - After Issue GB2447796C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88075507P 2007-01-16 2007-01-16
PCT/US2008/051214 WO2008089272A1 (en) 2007-01-16 2008-01-16 Formulations for cancer treatment

Publications (4)

Publication Number Publication Date
GB0807263D0 GB0807263D0 (en) 2008-05-28
GB2447796A GB2447796A (en) 2008-09-24
GB2447796B GB2447796B (en) 2009-03-04
GB2447796C true GB2447796C (en) 2009-11-12

Family

ID=39350967

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0807263A Withdrawn - After Issue GB2447796C (en) 2007-01-16 2008-01-16 Iodonitrobenzamide formulations for cancer and viral diseases.

Country Status (32)

Country Link
US (1) US20080176946A1 (cg-RX-API-DMAC7.html)
EP (2) EP2121139B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010516626A (cg-RX-API-DMAC7.html)
KR (1) KR20090113852A (cg-RX-API-DMAC7.html)
CN (1) CN101668561A (cg-RX-API-DMAC7.html)
AU (1) AU2008206294A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0806590A2 (cg-RX-API-DMAC7.html)
CA (1) CA2674600A1 (cg-RX-API-DMAC7.html)
CO (1) CO6220840A2 (cg-RX-API-DMAC7.html)
CR (1) CR10975A (cg-RX-API-DMAC7.html)
CY (1) CY1113819T1 (cg-RX-API-DMAC7.html)
DK (1) DK2121139T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2009000178A (cg-RX-API-DMAC7.html)
EC (1) ECSP099577A (cg-RX-API-DMAC7.html)
ES (1) ES2395690T3 (cg-RX-API-DMAC7.html)
GB (1) GB2447796C (cg-RX-API-DMAC7.html)
GT (1) GT200900201A (cg-RX-API-DMAC7.html)
HR (1) HRP20120960T1 (cg-RX-API-DMAC7.html)
IL (1) IL199682A0 (cg-RX-API-DMAC7.html)
MA (1) MA34559B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009007596A (cg-RX-API-DMAC7.html)
NZ (1) NZ579098A (cg-RX-API-DMAC7.html)
PL (1) PL2121139T3 (cg-RX-API-DMAC7.html)
PT (1) PT2121139E (cg-RX-API-DMAC7.html)
RS (1) RS52633B (cg-RX-API-DMAC7.html)
RU (2) RU2481830C2 (cg-RX-API-DMAC7.html)
SG (1) SG178714A1 (cg-RX-API-DMAC7.html)
SI (1) SI2121139T1 (cg-RX-API-DMAC7.html)
SV (1) SV2009003335A (cg-RX-API-DMAC7.html)
TN (1) TN2009000292A1 (cg-RX-API-DMAC7.html)
UA (1) UA100852C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008089272A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7961081B2 (en) * 2003-05-22 2011-06-14 John Tomlienovic Anti-theft system and method
AU2006257815A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. PARP modulators and treatment of cancer
KR20130028149A (ko) 2005-07-18 2013-03-18 바이파 사이언스 인코포레이티드 암의 치료
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
AU2007292387A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
JP2010502731A (ja) 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法
JP2011500684A (ja) * 2007-10-19 2011-01-06 バイパー サイエンシズ，インコーポレイティド ベンゾピロン系ｐａｒｐ阻害剤を用いる癌の処置方法および組成物
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
WO2009100159A2 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
US8026271B2 (en) * 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
MX2011003277A (es) * 2008-10-14 2012-09-21 Salubrious Pharmaceuticals LLC Proceso para el tratamiento de la artritis reumatoide, temblores/enfermedad de parkinson, esclerosis multiple y cancer de tipo no viral.
US20140051737A1 (en) * 2011-05-10 2014-02-20 Universite Laval Methods for the treatment and diagnostic of pulmonary arterial hypertension
EA028246B1 (ru) * 2012-11-30 2017-10-31 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Фармацевтическая композиция
WO2017192618A1 (en) * 2016-05-02 2017-11-09 Symbios Technologies, Inc. Electrochemical plasma activated aqueous chemotherapeutics
WO2018237327A1 (en) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. Methods of treating glioblastoma
EA202090573A1 (ru) 2017-09-26 2020-09-07 Тесаро, Инк. Составы нирапариба
US11628144B2 (en) 2017-09-29 2023-04-18 Triact Therapeutics, Inc. Iniparib formulations and uses thereof
WO2020246737A1 (ko) * 2019-06-04 2020-12-10 사회복지법인 삼성생명공익재단 콰시노이드를 포함하는 거세 저항성 전립선암 치료용 조성물
CZ309587B6 (cs) * 2021-01-22 2023-05-03 Oncora S.R.O. Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy
GB2611315B (en) * 2021-09-29 2024-01-03 Siemens Healthcare Gmbh Method of operating a magnetic resonance scanner
US20250372199A1 (en) * 2022-06-10 2025-12-04 Dana-Farber Cancer Institute, Inc. Allelic imbalance of chromatin accessibility in cancer identifies causal risk variants and their mechanisms

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0348655A (ja) * 1989-07-14 1991-03-01 Shionogi & Co Ltd プロスタグランジンｄ↓２類の安定化
US5633282A (en) * 1990-05-25 1997-05-27 British Technology Group Limited Inhibition of viral infection
US5232735A (en) * 1990-06-01 1993-08-03 Bioresearch, Inc. Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
US5631038A (en) * 1990-06-01 1997-05-20 Bioresearch, Inc. Specific eatable taste modifiers
US5637618A (en) * 1990-06-01 1997-06-10 Bioresearch, Inc. Specific eatable taste modifiers
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5877185A (en) * 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5652260A (en) * 1991-10-22 1997-07-29 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compound useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5516941A (en) * 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5482975A (en) * 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5558855A (en) 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
US6008250A (en) * 1993-05-26 1999-12-28 Bioresearch, Inc. Specific eatable taste modifiers
US6015792A (en) * 1993-05-26 2000-01-18 Bioresearch, Inc. Specific eatable taste modifiers
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
AU5780696A (en) * 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
US5837729A (en) * 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
US6225323B1 (en) * 1997-04-10 2001-05-01 Joseph Koziak Activated iododerivatives for the treatment of cancer and AIDS
US5908861A (en) * 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
EP1348432A4 (en) * 2001-01-04 2005-08-10 Daiichi Seiyaku Co CYCLODEXTRIN-CONTAINING PHARMACEUTICAL COMPOSITION
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
NZ541659A (en) * 2003-01-14 2007-05-31 Teva Pharma Pharmaceutical composition comprising with a pH between 4 and 9 to treat SLE comprising an aqueous carrier, a pharmaceutically acceptable salt of a peptide and a substituted beta-cyclodextrin
WO2005023765A1 (en) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
AU2006257815A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. PARP modulators and treatment of cancer
KR20130028149A (ko) * 2005-07-18 2013-03-18 바이파 사이언스 인코포레이티드 암의 치료
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
US20080076778A1 (en) * 2006-09-05 2008-03-27 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
JP2010502731A (ja) * 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法
AU2007292387A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof

Also Published As

Publication number Publication date
BRPI0806590A2 (pt) 2013-07-23
SI2121139T1 (sl) 2013-01-31
EP2476461A3 (en) 2012-10-24
ECSP099577A (es) 2009-10-30
MX2009007596A (es) 2009-08-13
SG178714A1 (en) 2012-03-29
PT2121139E (pt) 2012-12-12
NZ579098A (en) 2012-07-27
EP2121139B1 (en) 2012-10-10
GB2447796B (en) 2009-03-04
PL2121139T3 (pl) 2013-03-29
UA100852C2 (ru) 2013-02-11
US20080176946A1 (en) 2008-07-24
RU2009130599A (ru) 2011-02-27
DK2121139T3 (da) 2013-01-14
RS52633B (sr) 2013-06-28
IL199682A0 (en) 2010-04-15
HK1137158A1 (en) 2010-07-23
TN2009000292A1 (en) 2010-12-31
JP2010516626A (ja) 2010-05-20
DOP2009000178A (es) 2009-10-31
RU2012151571A (ru) 2014-06-10
CR10975A (es) 2009-10-15
CO6220840A2 (es) 2010-11-19
GT200900201A (es) 2011-06-23
CN101668561A (zh) 2010-03-10
AU2008206294A1 (en) 2008-07-24
EP2121139A1 (en) 2009-11-25
HRP20120960T1 (hr) 2012-12-31
CA2674600A1 (en) 2008-07-24
RU2481830C2 (ru) 2013-05-20
HK1121697A1 (zh) 2009-04-30
CY1113819T1 (el) 2016-07-27
GB2447796A (en) 2008-09-24
KR20090113852A (ko) 2009-11-02
ES2395690T3 (es) 2013-02-14
EP2476461A2 (en) 2012-07-18
SV2009003335A (es) 2010-02-05
MA34559B1 (fr) 2013-10-02
GB0807263D0 (en) 2008-05-28
WO2008089272A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
GB2447796C (en) Iodonitrobenzamide formulations for cancer and viral diseases.
GB2435419B (en) Formulations
GB0711656D0 (en) Formulations
IL202648A0 (en) Antibody formulations
ZA200804918B (en) Therapeutic vaccine
EP2000424A4 (en) DRUGS CART
ZA200908969B (en) Formulations
AP2011005695A0 (en) Therapeutic antiviral poptides.
IL211670A (en) Preparations containing therapeutic antibodies against steap-1
GB0809979D0 (en) Formulations
GB0718346D0 (en) Tooth-bleaching preparations
GB0610336D0 (en) Formulations
IL198160A0 (en) Pharmaceutical formulations
GB0718404D0 (en) Formulations
EP2167635A4 (en) ANTIBODY FORMULATIONS
HK1121697B (en) Iodonitrobenzamide formulations for cancer and viral diseases
GB0706940D0 (en) Drugs against cancer infectious diseases
GB0801441D0 (en) Drugs against cancer and infectious diseases
GB0622142D0 (en) Aids & cancer cure + vaccine
GB0706538D0 (en) Cancer therapeutic
GB0606702D0 (en) Cancer therapeutic
GB0612259D0 (en) Cancer therapeutic
GB0713093D0 (en) Pharmaceutical formulations
GB0705781D0 (en) Drugs against cancer and infectious diseases
GB0710900D0 (en) Formulations

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1121697

Country of ref document: HK

S27 Amendment of specification after grant (sect. 27/patents act 1977)

Free format text: APPLICATION FILED; APPLICATION TO AMEND SPECIFICATION UNDER SECTION 27 FILED ON 27 FEBRUARY 2009

S27 Amendment of specification after grant (sect. 27/patents act 1977)

Free format text: APPLICATION OPEN FOR OPPOSITION

S27 Amendment of specification after grant (sect. 27/patents act 1977)

Free format text: SPECIFICATION AMENDED

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1121697

Country of ref document: HK

S29 Surrender of patent (sect. 29/pat. act 1977)

Free format text: OFFER FILED; APPLICATION FILED ON 5 DECEMBER 2013

S29 Surrender of patent (sect. 29/pat. act 1977)

Free format text: OFFER ACCEPTED